Targeting mitochondrial dynamics and redox regulation in cardiovascular diseases.

Autor: Beg MA; Versiti Blood Research Institute, Milwaukee, WI 53226, USA., Huang M; HD Biosciences Inc. a WuXi AppTec company, San Diego, CA 92121, USA., Vick L; Department of Biochemistry, Medical College of Wisconsin, Milwaukee, WI 53226, USA., Rao KNS; Joint Department of Biomedical Engineering, Medical College of Wisconsin & Marquette University, Milwaukee, WI 53226, USA., Zhang J; Versiti Blood Research Institute, Milwaukee, WI 53226, USA., Chen Y; Versiti Blood Research Institute, Milwaukee, WI 53226, USA; Department of Medicine, Medical College of Wisconsin, Milwaukee, WI 53226, USA. Electronic address: yilchen@mcw.edu.
Jazyk: angličtina
Zdroj: Trends in pharmacological sciences [Trends Pharmacol Sci] 2024 Apr; Vol. 45 (4), pp. 290-303. Date of Electronic Publication: 2024 Mar 07.
DOI: 10.1016/j.tips.2024.02.001
Abstrakt: Accumulating evidence highlights the pivotal role of mitochondria in cardiovascular diseases (CVDs). Understanding the molecular mechanisms underlying mitochondrial dysfunction is crucial for developing targeted therapeutics. Recent years have seen substantial advancements in unraveling mitochondrial regulatory pathways in both normal and pathological states and the development of potent drugs. However, specific delivery of drugs into the mitochondria is still a challenge. We present recent findings on regulators of mitochondrial dynamics and reactive oxygen species (ROS), critical factors influencing mitochondrial function in CVDs. We also discuss advancements in drug delivery strategies aimed at overcoming the technical barrier in targeting mitochondria for CVD treatment.
Competing Interests: Declaration of interests The authors declare no conflict of interest.
(Copyright © 2024 Elsevier Ltd. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: